ONCAlert | Upfront Therapy for mRCC
Videos  >  

Phase III CASSIOPEIA Impacts Treatment Decisions in Patients With Multiple Myeloma

Pieter Sonneveld, MD, PhD
Published Online:2:54 PM, Wed October 9, 2019


Pieter Sonneveld, MD, PhD, professor of hematology and head of the Department of Hematology at Erasmus MC Cancer Institute in The Netherlands, discusses how the findings from the phase III CASSIOPEIA trial inform current thinking about treating patients with multiple myeloma.

Sonneveld says that not only high-risk patients but all those who are transplant-eligible and newly diagnosed may potentially have a new standard of care in the future. The new standard will come from the combination of daratumumab (Darzalex) and bortezomib (Velcade) plus thalidomide (Thalomid; VTd), or the regimen of bortezomib, lenalidomide (Revlimid), dexamethasone (VRd), or other triple-drug combinations going to a 4-drug regimen, including daratumumab.

More data is still necessary before this can happen, including the results from the second randomized part of the study that involved daratumumab as maintenance. However, Sonneveld says they have submitted data to the regulatory bodies based on the first part of the trial. He assumes that in the older patients, adding daratumumab will become standard for the initial treatment of patients.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.